MedPath

Tramadol

Generic Name
Tramadol
Brand Names
Conzip, Durela, Qdolo, Ralivia, Ryzolt, Seglentis, Tridural, Ultracet, Ultram, Zytram
Drug Type
Small Molecule
Chemical Formula
C16H25NO2
CAS Number
27203-92-5
Unique Ingredient Identifier
39J1LGJ30J

Overview

Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.

Indication

Tramadol is approved for the management of moderate to severe pain in adults. Tramadol is also used off-label in the treatment of premature ejaculation.

Associated Conditions

  • Acute Pain
  • Premature Ejaculation
  • Severe Pain
  • Acute, moderate, severe Pain
  • Moderate Pain

Research Report

Published: Jul 21, 2025

A Comprehensive Monograph on Tramadol (DrugBank ID: DB00193): Pharmacology, Clinical Use, and Safety Profile

Executive Summary

Tramadol is a centrally-acting synthetic analgesic used for the management of moderate to moderately severe pain in adults. Identified by DrugBank ID DB00193 and CAS Number 27203-92-5, it is classified as a small molecule drug. Its clinical utility is derived from a unique, dual mechanism of action that distinguishes it from traditional opioid analgesics. Tramadol functions as a weak agonist at the µ-opioid receptor and simultaneously inhibits the reuptake of serotonin and norepinephrine (SNRI), thereby modulating both opioid-mediated and monoaminergic descending pain pathways. This multimodal activity contributes to its efficacy across a spectrum of pain conditions, including neuropathic and chronic pain, and positions it as a Step 2 option on the World Health Organization's pain ladder.

The drug is administered as a racemic mixture of its (+)- and (-)-enantiomers, which act synergistically. The (+)-enantiomer and its primary active metabolite, O-desmethyltramadol (M1), are responsible for the µ-opioid receptor agonism and serotonin reuptake inhibition, while the (-)-enantiomer primarily inhibits norepinephrine reuptake. The conversion of tramadol to the more potent M1 metabolite is critically dependent on the cytochrome P450 2D6 (CYP2D6) enzyme. Genetic polymorphisms in CYP2D6 lead to significant inter-individual variability in analgesic response and toxicity risk. "Ultra-rapid metabolizers" are at high risk for opioid toxicity, including life-threatening respiratory depression, a fact highlighted in a specific FDA Black Box Warning that has led to contraindications in pediatric populations.

Continue reading the full research report

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2016/11/08
Phase 4
UNKNOWN
University of Illinois College of Medicine at Peoria
2016/09/26
Not Applicable
Completed
2016/08/01
Phase 4
Completed
2016/07/29
Phase 4
Completed
2016/07/21
Phase 2
Completed
Iuliu Hatieganu University of Medicine and Pharmacy
2016/07/11
Phase 4
UNKNOWN
2016/07/07
Not Applicable
UNKNOWN
Eskisehir Osmangazi University
2016/05/19
Phase 4
Completed
Menarini Group
2016/05/04
Phase 3
UNKNOWN
2016/04/13
Phase 3
UNKNOWN

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Proficient Rx LP
63187-615
ORAL
150 mg in 1 1
2/1/2020
Macleods Pharmaceuticals Limited
33342-537
ORAL
50 mg in 1 1
9/15/2023
Bryant Ranch Prepack
63629-8324
ORAL
300 mg in 1 1
1/19/2022
Sun Pharmaceutical Industries, Inc.
47335-861
ORAL
300 mg in 1 1
12/12/2023
REMEDYREPACK INC.
70518-1254
ORAL
50 mg in 1 1
2/15/2024
Galephar Pharmaceutical Research Inc.
66277-242
ORAL
300 mg in 1 1
12/19/2022
Physicians Total Care, Inc.
54868-4263
ORAL
200 mg in 1 1
11/19/2010
Aidarex Pharmaceuticals LLC
53217-040
ORAL
37.5 mg in 1 1
10/28/2014
Galephar Pharmaceutical Research Inc.
66277-253
ORAL
200 mg in 1 1
5/21/2010
Rebel Distributors Corp
21695-236
ORAL
37.5 mg in 1 1
4/22/2010

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Sign in to access additional TGA-approved drug information with detailed regulatory data.

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

View More Health Canada Approvals

Sign in to access additional Health Canada approved drug information with detailed regulatory data.

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

View More CIMA AEMPS Approvals

Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

View More Philippines FDA Approvals

Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

View More Saudi SFDA Approvals

Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

View More Malaysia NPRA Approvals

Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

View More UK EMC Drug Information

Sign in to access additional UK EMC drug information with detailed pharmaceutical data.

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.